Free Trial

Jane Street Group LLC Sells 284,299 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Heron Therapeutics logo with Medical background

Jane Street Group LLC reduced its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 85.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 47,827 shares of the biotechnology company's stock after selling 284,299 shares during the period. Jane Street Group LLC's holdings in Heron Therapeutics were worth $73,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of HRTX. New York State Common Retirement Fund lifted its holdings in shares of Heron Therapeutics by 3.2% in the 4th quarter. New York State Common Retirement Fund now owns 1,321,006 shares of the biotechnology company's stock valued at $2,021,000 after buying an additional 41,062 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Heron Therapeutics by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company's stock worth $1,692,000 after acquiring an additional 9,418 shares during the last quarter. Northern Trust Corp raised its position in shares of Heron Therapeutics by 2.2% in the fourth quarter. Northern Trust Corp now owns 1,011,756 shares of the biotechnology company's stock valued at $1,548,000 after buying an additional 21,769 shares during the last quarter. CM Management LLC boosted its holdings in shares of Heron Therapeutics by 40.0% during the 4th quarter. CM Management LLC now owns 700,000 shares of the biotechnology company's stock worth $1,071,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Richmond Brothers Inc. grew its holdings in Heron Therapeutics by 25.8% in the 4th quarter. Richmond Brothers Inc. now owns 642,339 shares of the biotechnology company's stock valued at $983,000 after buying an additional 131,557 shares in the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on HRTX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, April 11th. Wall Street Zen upgraded shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Finally, HC Wainwright assumed coverage on shares of Heron Therapeutics in a report on Monday. They issued a "buy" rating and a $6.00 target price on the stock.

View Our Latest Stock Report on Heron Therapeutics

Heron Therapeutics Price Performance

HRTX stock traded down $0.05 during trading on Thursday, reaching $2.01. 702,633 shares of the stock traded hands, compared to its average volume of 2,230,790. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93. The firm has a market capitalization of $306.65 million, a PE ratio of -11.17 and a beta of 1.16. The business's 50 day moving average price is $2.01 and its 200-day moving average price is $1.88.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The business had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. On average, equities research analysts predict that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Heron Therapeutics Profile

(Free Report)

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Should You Invest $1,000 in Heron Therapeutics Right Now?

Before you consider Heron Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.

While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines